While the news on patients hospitalized with COVID-19 was not as hoped, the ability to positively impact outcomes when identified early is promising.

Eli Lilly Chairman and CEO Dave Ricks told CNBC on Tuesday that he believes the company’s coronavirus antibody treatment will still be beneficial to Covid-19 patients, despite the recent end to a study of the drug in a hospital setting.

To watch the interview, click here.

Bio Link As a partner at Michael Best Strategies, Kristine works with healthcare clients to optimize their business strategy, evaluate potential mergers and expansions, and discover alternate distribution and product strategies. Her experience in the payer, provider, and integrated health system arenas allows her to work with clients to differentiate their products and services in a highly competitive marketplace. Expertise: Healthcare Market Development, Business Growth Strategy, Sales & Distribution, and Healthcare Start-ups and Innovation


Please enter your comment!
Please enter your name here